Y-mAbs Therapeutics YMAB Stock
Y-mAbs Therapeutics Price Chart
Y-mAbs Therapeutics YMAB Financial and Trading Overview
| Y-mAbs Therapeutics stock price | 14.37 USD |
| Previous Close | 8.51 USD |
| Open | 8.66 USD |
| Bid | 8 USD x 800 |
| Ask | 8.02 USD x 800 |
| Day's Range | 7.95 - 8.79 USD |
| 52 Week Range | 2.7 - 20.48 USD |
| Volume | 303.51K USD |
| Avg. Volume | 738.76K USD |
| Market Cap | 349.86M USD |
| Beta (5Y Monthly) | 0.762913 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.49 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.71 USD |
YMAB Valuation Measures
| Enterprise Value | 280.55M USD |
| Trailing P/E | N/A |
| Forward P/E | -11.955224 |
| PEG Ratio (5 yr expected) | 0.1 |
| Price/Sales (ttm) | 4.6628 |
| Price/Book (mrq) | 3.2442284 |
| Enterprise Value/Revenue | 3.739 |
| Enterprise Value/EBITDA | -4.852 |
Trading Information
Y-mAbs Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.762913 |
| 52-Week Change | -30.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 20.48 USD |
| 52 Week Low | 2.7 USD |
| 50-Day Moving Average | 7.65 USD |
| 200-Day Moving Average | 7.24 USD |
YMAB Share Statistics
| Avg. Volume (3 month) | 738.76K USD |
| Avg. Daily Volume (10-Days) | 240.2K USD |
| Shares Outstanding | 43.68M |
| Float | 27.44M |
| Short Ratio | 3.77 |
| % Held by Insiders | 12.34% |
| % Held by Institutions | 61.80% |
| Shares Short | 1.65M |
| Short % of Float | 4.54% |
| Short % of Shares Outstanding | 3.78% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -98.47% |
| Operating Margin (ttm) | -78.15% |
| Gross Margin | 89.57% |
| EBITDA Margin | -77.055% |
Management Effectiveness
| Return on Assets (ttm) | -22.31% |
| Return on Equity (ttm) | -55.70% |
Income Statement
| Revenue (ttm) | 75.03M USD |
| Revenue Per Share (ttm) | 1.72 USD |
| Quarterly Revenue Growth (yoy) | 93.10% |
| Gross Profit (ttm) | 57.7M USD |
| EBITDA | -57817000 USD |
| Net Income Avi to Common (ttm) | -73890000 USD |
| Diluted EPS (ttm) | -1.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 92.63M USD |
| Total Cash Per Share (mrq) | 2.12 USD |
| Total Debt (mrq) | 1.48M USD |
| Total Debt/Equity (mrq) | 1.38 USD |
| Current Ratio (mrq) | 4.784 |
| Book Value Per Share (mrq) | 2.469 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -64120000 USD |
| Levered Free Cash Flow (ttm) | -22898876 USD |
Profile of Y-mAbs Therapeutics
| Country | United States |
| State | NY |
| City | New York |
| Address | 230 Park Avenue |
| ZIP | 10169 |
| Phone | 646 885 8505 |
| Website | https://www.ymabs.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 147 |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Q&A For Y-mAbs Therapeutics Stock
What is a current YMAB stock price?
Y-mAbs Therapeutics YMAB stock price today per share is 14.37 USD.
How to purchase Y-mAbs Therapeutics stock?
You can buy YMAB shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Y-mAbs Therapeutics?
The stock symbol or ticker of Y-mAbs Therapeutics is YMAB.
Which industry does the Y-mAbs Therapeutics company belong to?
The Y-mAbs Therapeutics industry is Biotechnology.
How many shares does Y-mAbs Therapeutics have in circulation?
The max supply of Y-mAbs Therapeutics shares is 43.78M.
What is Y-mAbs Therapeutics Price to Earnings Ratio (PE Ratio)?
Y-mAbs Therapeutics PE Ratio is now.
What was Y-mAbs Therapeutics earnings per share over the trailing 12 months (TTM)?
Y-mAbs Therapeutics EPS is -0.49 USD over the trailing 12 months.
Which sector does the Y-mAbs Therapeutics company belong to?
The Y-mAbs Therapeutics sector is Healthcare.
Y-mAbs Therapeutics YMAB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}